UA37244C2 - Спосіб лікування або профілактики клінічних розладів, виліковних прогестероном, у пацієнтів жіночої статі - Google Patents

Спосіб лікування або профілактики клінічних розладів, виліковних прогестероном, у пацієнтів жіночої статі

Info

Publication number
UA37244C2
UA37244C2 UA96030993A UA96030993A UA37244C2 UA 37244 C2 UA37244 C2 UA 37244C2 UA 96030993 A UA96030993 A UA 96030993A UA 96030993 A UA96030993 A UA 96030993A UA 37244 C2 UA37244 C2 UA 37244C2
Authority
UA
Ukraine
Prior art keywords
progesterone
curable
treating
female patients
clinical disorders
Prior art date
Application number
UA96030993A
Other languages
English (en)
Russian (ru)
Inventor
Вілльям Джозеф Бологна
Вильям Джозеф Болонья
Ховард Леслі Левайн
Ховард Лесли Левайн
Original Assignee
Колумбіа Лабораторіс (Бірмуда) Лімітед
Колумбиа Лабораторис (Бирмуда) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22402302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA37244(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Колумбіа Лабораторіс (Бірмуда) Лімітед, Колумбиа Лабораторис (Бирмуда) Лимитед filed Critical Колумбіа Лабораторіс (Бірмуда) Лімітед
Publication of UA37244C2 publication Critical patent/UA37244C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Спосіб лікування або профілактики клінічних розладів, виліковних прогестероном, у пацієнтів жіночої статі, включає введення в піхву лікарського засобу, що містить прогестерон і фармацевтично прийнятний носій, який є зшитим полікарбоксильним полімером. Лікарський засіб вводять в кількості, достатній для того, щоб викликати секреторне перетворення ендометрію при підтриманні рівня прогестерону в сироватці не вище 6 нг/мл протягом періоду щонайменш 48 годин.
UA96030993A 1993-09-15 1994-09-13 Спосіб лікування або профілактики клінічних розладів, виліковних прогестероном, у пацієнтів жіночої статі UA37244C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/122,371 US5543150A (en) 1993-09-15 1993-09-15 Method of progesterone delivery and affect thereof
PCT/US1994/010270 WO1995007699A1 (en) 1993-09-15 1994-09-13 Novel method of progesterone delivery and affect thereof

Publications (1)

Publication Number Publication Date
UA37244C2 true UA37244C2 (uk) 2001-05-15

Family

ID=22402302

Family Applications (1)

Application Number Title Priority Date Filing Date
UA96030993A UA37244C2 (uk) 1993-09-15 1994-09-13 Спосіб лікування або профілактики клінічних розладів, виліковних прогестероном, у пацієнтів жіночої статі

Country Status (27)

Country Link
US (1) US5543150A (uk)
EP (1) EP0719146B1 (uk)
JP (1) JP3143474B2 (uk)
KR (1) KR100278553B1 (uk)
AT (1) ATE174796T1 (uk)
BR (1) BR9407475A (uk)
CA (1) CA2171939C (uk)
CO (1) CO4290332A1 (uk)
DE (1) DE69415543T2 (uk)
DK (1) DK0719146T3 (uk)
ES (1) ES2126783T3 (uk)
FI (1) FI115444B (uk)
GR (1) GR3029314T3 (uk)
HU (1) HU221583B (uk)
IL (1) IL110972A (uk)
LT (1) LT4072B (uk)
LV (1) LV11527B (uk)
MA (1) MA23329A1 (uk)
MY (1) MY111484A (uk)
NO (1) NO308585B1 (uk)
NZ (1) NZ273816A (uk)
PE (1) PE50795A1 (uk)
PH (1) PH30813A (uk)
RU (1) RU2148393C1 (uk)
UA (1) UA37244C2 (uk)
WO (1) WO1995007699A1 (uk)
ZA (1) ZA947073B (uk)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869081A (en) * 1996-06-28 1999-02-09 The Population Council Progesterone vaginal ring for treatment of infertility
US5985861A (en) * 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US6056972A (en) * 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
US6602487B1 (en) 1997-02-26 2003-08-05 Dimera Incorporated Methods and tests for producing and for inhibiting coronary artery vasospasms
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
EP1356806A1 (en) * 1997-09-12 2003-10-29 Columbia Laboratories (Bermuda) Limited A pharmaceutical composition for treating dysmenorrhea and premature labor
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US20040234606A1 (en) * 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
CA2316296A1 (en) * 1997-10-10 1999-04-22 Imperial College Of Science, Technology And Medicine Use of csaidtm compounds for the management of uterine contractions
US6306914B1 (en) * 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
WO1999059595A1 (en) * 1998-05-20 1999-11-25 Wiley Teresa S Progesterone treatment of cancer
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US20070178139A1 (en) * 1998-11-18 2007-08-02 Yankov Vladimir I Vaginally administratable progesterone-containing tablets and method for preparing same
US6479045B2 (en) 1999-12-22 2002-11-12 Columbia Laboratories, Inc. Vaginal pH buffering for preventing miscarriage and premature labor, by treating or preventing bacterial vaginosis
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
NZ549469A (en) * 2001-02-15 2009-02-28 Access Pharma Inc Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US7709026B2 (en) 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
AU2004233997C1 (en) * 2003-04-29 2014-01-30 Massachusetts Institiute Of Technology Methods and devices for the sustained release of multiple drugs
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
UA90095C2 (en) * 2003-09-03 2010-04-12 Мискон Трейдинг С.А. Method for the treatment of endometriosis
HUE025239T2 (en) * 2003-09-03 2016-03-29 Miscon Trading S A Methods for treating endometriosis
US20060292223A1 (en) * 2005-06-16 2006-12-28 Warner Chilcott Company Inc, Gel compositions for topical administration
CA2612380C (en) * 2005-06-16 2017-06-06 Warner Chilcott Company, Inc. Estrogen compositions for vaginal administration
KR20090029237A (ko) * 2006-06-02 2009-03-20 피어 트리 파머슈티칼스 인코포레이티드 위축성 질염을 치료하는 방법
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
ES2310968B1 (es) 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.
JP2010539245A (ja) * 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
GB0723882D0 (en) * 2007-12-07 2008-01-23 Univ Leicester Methods for the detection of a threatened miscarriage
SI2359807T1 (sl) 2008-02-04 2017-10-30 Ferring B.V. Monolitni intravaginalni obroč, ki vsebuje progesteron ter postopki za njegovo izdelavo in uporabo
US9107696B2 (en) * 2008-08-06 2015-08-18 Emory University Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
US8421747B2 (en) 2008-09-24 2013-04-16 Microsoft Corporation Object detection and user settings
ES2344675B1 (es) 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
CN107260745A (zh) * 2010-03-22 2017-10-20 利普生物药剂公司 用于抗孕酮的非毒性递送的组合物和方法
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8435972B2 (en) 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
JP6010120B2 (ja) * 2011-07-15 2016-10-19 ウニベルシテイト ヘント 膣内送達システム
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2806742B1 (en) * 2012-01-26 2019-03-27 TherapeuticsMD, Inc. Transdermal hormone replacement therapies
ES2701400T3 (es) 2012-05-31 2019-02-22 Repros Therapeutics Inc Formulaciones para la administración vaginal de antiprogestinas
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6343619B2 (ja) 2012-11-02 2018-06-13 レプロス セラピューティクス インコーポレイティド プロゲステロン依存性病態を処置する方法およびその組成物
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103239389A (zh) * 2013-06-03 2013-08-14 南京泽恒医药技术开发有限公司 一种治疗先兆性流产的黄体酮缓释凝胶的制备方法
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
CN107847506A (zh) 2015-06-22 2018-03-27 来普卡公司 含17‑羟基孕酮酯的口服组合物和相关方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
JP7345398B2 (ja) * 2017-06-22 2023-09-15 ヴィラマル リミテッド 薬物送達のための組成物およびその使用方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3588620A (en) * 1969-08-06 1971-06-28 Gen Electric Electrical control device panel assembly with multifunctional insulating support means
EP0501523B1 (en) * 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US4916574A (en) * 1989-06-06 1990-04-10 Siemens Energy & Automation, Inc. Panelboard bus bar arrangement
DK0431719T3 (da) * 1989-10-31 1995-02-27 Columbia Lab Inc Vaginalt vævsbefugtende præparat
EP0599888A1 (de) * 1991-08-05 1994-06-08 Trawöger, Werner Mittel gegen beläge an benetzten oberflächen
TWI354439B (en) 2007-06-04 2011-12-11 Holtek Semiconductor Inc Ac signal producer and method thereof
US7862282B2 (en) 2008-07-24 2011-01-04 Autoliv Asp, Inc. Separation fastener with segmented washer

Also Published As

Publication number Publication date
JP3143474B2 (ja) 2001-03-07
HU221583B (hu) 2002-11-28
JPH09502724A (ja) 1997-03-18
NO961044L (no) 1996-05-14
WO1995007699A1 (en) 1995-03-23
PE50795A1 (es) 1996-01-19
EP0719146B1 (en) 1998-12-23
ZA947073B (en) 1995-05-02
KR100278553B1 (ko) 2001-01-15
NO308585B1 (no) 2000-10-02
AU689133B2 (en) 1998-03-26
IL110972A0 (en) 1994-11-28
AU7726194A (en) 1995-04-03
GR3029314T3 (en) 1999-05-28
NZ273816A (en) 2007-09-28
FI115444B (fi) 2005-05-13
NO961044D0 (no) 1996-03-14
LT4072B (en) 1996-11-25
US5543150A (en) 1996-08-06
LT96027A (en) 1996-07-25
HU9600669D0 (en) 1996-05-28
CO4290332A1 (es) 1996-04-17
HUT76824A (en) 1997-11-28
LV11527A (lv) 1996-10-20
ATE174796T1 (de) 1999-01-15
BR9407475A (pt) 1996-11-12
LV11527B (en) 1997-02-20
CA2171939C (en) 2002-01-01
IL110972A (en) 1998-03-10
MY111484A (en) 2000-06-30
DE69415543D1 (de) 1999-02-04
DK0719146T3 (da) 1999-08-23
FI961221A (fi) 1996-05-14
EP0719146A1 (en) 1996-07-03
ES2126783T3 (es) 1999-04-01
CA2171939A1 (en) 1995-03-23
MA23329A1 (fr) 1995-04-01
PH30813A (en) 1997-10-17
DE69415543T2 (de) 1999-06-17
RU2148393C1 (ru) 2000-05-10
FI961221A0 (fi) 1996-03-15

Similar Documents

Publication Publication Date Title
UA37244C2 (uk) Спосіб лікування або профілактики клінічних розладів, виліковних прогестероном, у пацієнтів жіночої статі
IE870993L (en) Nasal administration compositions.
HU9402771D0 (en) Pharmaceutical compositions for wound healing and treatment of fibrotic disorders
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
CA2129541A1 (en) Method of Promoting Nitrogen Retention in Humans
CA2001144A1 (en) Contraception system and method
RO116342B1 (ro) Compoziţie farmaceutică lichidă, orală
MY108496A (en) Hypoglycemic thiazolidine diones.
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
EP0269408A3 (en) Tgf-beta in the treatment of inflammatory disorders
AU1992592A (en) Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
EP0177342A3 (en) Oral formulation of therapeutic proteins
CA2158036A1 (en) 3,4-Diarylchromans for Treatment of Dermatitis
WO1994008613A3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy
GR3021828T3 (en) Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis.
AU6821687A (en) System for delivering drug with enhanced bioacceptability
AU2807689A (en) Method for the treatment of body tissues and the administration of drugs thereto
EP0306191A3 (en) 2,3-dihydroergolines for serotonergic function enhancement
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
CA2159485A1 (en) Anti-oxydant alkylaryl polyether alcohol polymers
周荣兴 et al. Hypotensive effect of ototherapy in relation to symptomatic and dispositional types of patients
EP0367302A3 (en) Process for semi-synthesis of human insulin, water-soluble cross-linked achromobacter protease i for use therein and a process for preparing the same
DE3878154D1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
AU5903690A (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e) azepine-6, 11-dione and derivatives as drugs for use in the treatment of urinary incontinence